The CHA2DS2-VASc score is a crucial tool in modern cardiology, designed to assess the risk of stroke in patients diagnosed with atrial fibrillation (AF). This article delves into the intricacies of the CHA2DS2-VASc score, its development, validation, and application in clinical practice. Additionally, we will explore the relationship between the CHA2DS2-VASc score and the HAS-BLED score, which assesses bleeding risk in AF patients.
What is the CHA2DS2-VASc Score?
The CHA2DS2-VASc score is used for long-term stroke risk stratification in patients with atrial fibrillation (AF). It is one of several stroke risk stratification schemas that can help determine the 1-year risk of a thromboembolic event in nonanticoagulated patients with nonvalvular AF.
The CHA2DS2-VASc score calculates stroke risk for patients with atrial fibrillation. The CHA2DS2-VASc score was developed following the identification of additional stroke risk factors in patients with AF using the Birmingham 2009 stroke risk stratification schema (Lip 2010).
Scores were calculated according to congestive heart failure (1 point), hypertension (1 point), age >75 years (2 points), diabetes (1 point) and prior stroke (2 points), age >65 (1 point), female sex (1 point) and vascular disease (1 point). To assess the risk of bleeding, we used the HAS-BLED score that relies on hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio (INR), elderly (age ≥65 years), and drugs/alcohol simultaneously [15].
Components of the CHA2DS2-VASc Score
- C - Congestive Heart Failure (1 point)
- H - Hypertension (1 point)
- A2 - Age ≥75 years (2 points)
- D - Diabetes Mellitus (1 point)
- S2 - Prior Stroke or TIA (2 points)
- V - Vascular Disease (1 point)
- A - Age 65-74 years (1 point)
- Sc - Sex Category (Female = 1 point)
The study found that as the CHA2DS2-VASc score increased, the rate of thromboembolic events within 1 year in nonanticoagulated patients with nonvalvular AF also increased. No thromboembolic events were recorded in cohort patients who were classified as low risk by the Birmingham 2009 schema (score = 0).
Read also: Living in Chadds Ford Township
There was no statistically significant difference found between the CHA2DS2-VASc and CHADS2 risk stratification scores in predicting thromboembolic events. A subsequent study examining the performance of CHA2DS2-VASc in predicting thromboembolic events for anticoagulated patients identified coronary artery disease and smoking as potential additional risk factors for thromboembolic events in this subset of patients.
The CHA2DS2 VASc score is an updated version of CHADS2, and it aims to stratify AF patients according to their risk of developing an ischemic stroke [24]. In our study, 83.0% of females and 77.9% of males had a high risk of stroke. The female gender was found to be an independent risk factor for stroke.
Meta-analyses have found that women have an increased risk of stroke compared with men, regardless of oral anticoagulation therapy [25]. This led to the evolution of risk stratification models to include the female gender as a risk score, including the CHA2DS2 VASc score, Framingham stroke risk score, and the European Society of Cardiology (ESC), the American College of Cardiology (ACC), and the American Heart Association (AHA) guidelines [4].
Clinical Implications and Anticoagulation
Carefully evaluate all of the risks and benefits prior to initiating anticoagulation in patients with nonvalvular AF. Consider not starting anticoagulation in patients with nonvalvular AF and a CHA2DS2-VASc score of 0, as these patients had no thromboembolic events in the original study. When anticoagulation is considered, tools such as the ATRIA bleeding risk score can be used to determine the risk for warfarin-associated hemorrhage.
On the other hand, the use of DOACs in AF patients is associated with an increased risk of bleeding events [6]. Therefore, an accurate stratification of risks for stroke or bleeding should guide the use and dosage of antithrombotic treatments.
Read also: Expert HVAC Solutions in Montgomery
Also, 63.7% of patients with a low risk of bleeding have a high risk of stroke, which can justify the value of using anticoagulants in this group of patients. This could be attributed to the higher specificity of HAS-BLED, but some predictability of CHA2DS2 VASc score for bleeding as well [26, 27].
The HAS-BLED Score: Assessing Bleeding Risk
The HAS-BLED score can help guide the decision on whether to start anticoagulation in patients with atrial fibrillation (AF). It can be used instead of, or in conjunction with, other bleeding risk scores such as ATRIA and HEMORR2HAGES to determine the risk of major bleeding in a patient with AF. Consider comparing the risk for major bleeding as calculated by the HAS-BLED score to the risk for thromboembolic events as calculated by the CHADS2 or CHA2DS2-VASc scores to determine if the benefit of anticoagulation outweighs the risk. Clinical factors that contribute to stroke risk and support anticoagulation in patients with AF are frequently risk factors for bleeding as well.
The HAS-BLED score was developed as a practical risk score to estimate the 1-year risk for major bleeding in patients with AF (Pisters 2010). The study included 5333 ambulatory and hospitalized patients with AF from both academic and nonacademic hospitals in 35 member countries of the European Society for Cardiology. Patients were followed up at 1 year to determine survival and major adverse cardiovascular events, such as major bleeding.
Components of the HAS-BLED Score
- H - Hypertension (uncontrolled systolic >160 mmHg) (1 point)
- A - Abnormal Renal/Liver Function (1 or 2 points)
- S - Stroke History (1 point)
- B - Bleeding History or Predisposition (1 point)
- L - Labile INR (if on Warfarin) (1 point)
- E - Elderly (age >65 years) (1 point)
- D - Drugs (antiplatelet/NSAIDs) or Alcohol Use (1 or 2 points)
CHADS-VASc Score for Atrial Fibrillation - MEDZCOOL
As for bleeding, we incorporated the HAS-BLED score to assess this risk. Although CHADS2 and CHA2DS2 VASc scores are correlated with bleeding, a study found that in the multivariate analysis, they lose statistical significance after adjusting for HAS-BLED scores [26]. This suggests that HAS-BLED has a better predictive performance for bleeding events [27].
Almost half of the patients in our study had a low risk of bleeding, 31.5% had intermediate risk, and 19.6% had a high risk according to the HAS-BLED score. We also found that almost all patients with a high HAS-BLED score have high CHA2DS2 VASc scores, which indicates that risks of stroke and bleeding coexist in these patients.
Read also: North Carolina's Popcorn History
In almost all NVAF patients with a high risk of bleeding (high HAS-BLED score), the use of anticoagulants is highly recommended according to the CHA2DS2 VASc score stratification.
The JoFib Registry: A Middle Eastern Perspective
This study evaluated NVAF patients from the JoFib Registry [11, 12]. Out of 2000 AF patients in the JoFib Registry [11, 12], we evaluated epidemiological and clinical data of 1823 (91.2%) NVAF patients. The other 177 (8.2%) patients had a valvular AF mainly related to rheumatic heart disease.
The present study aimed to report if there is any concordance between the CHA2DS2 VASc score (determining the need for anticoagulants therapy) and Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) scores (determining the risk for bleeding and the need for dose adjustment when using OACs) in Middle Eastern patients with NVAF.
In our study, 83.0% of females and 77.9% of males had a high risk of stroke. The female gender was found to be an independent risk factor for stroke. As indicated by our results, increasing the risk for bleeding in the patients (high HASBLED category) was associated with increasing the risk for complications (high CHA2DS2 VASc category) and consequently increasing the risk for death.
In the Middle East, only a minimum number of studies have been carried out on AF. Although the sample size is sufficient, this study is descriptive, and our analysis does not conclude definitive answers for the validity of CHA2DS2 VASc and HAS-BLED for Middle Eastern AF patients, which still requires further investigation.
Key Findings from the JoFib Registry
- Females had a significantly higher CHA2DS2 VASc score than males (p=0.012).
- 48.9% of patients had a low risk of bleeding, 31.5% had intermediate risk, and 19.6% had a high risk.
- A correlation was found between the two scoring systems.
PREFER in AF Registry
Individual patient data were pooled from the PREvention oF thromboembolic events-European Registry in Atrial Fibrillation (PREFER in AF), a prospective registry of 7243 AF patients from 461 hospitals and 7 European countries (Austria, France, Germany, Italy, Spain, Switzerland, and the United Kingdom) conducted between January 2012 and January 2013, with 1-year follow-up.
In 5209 AF patients with complete information on both scores, average one-year mortality was 3.1%. We found strong gradients between stroke/systemic embolic events (SSE), major bleeding and-specifically-mortality for both CHA2DS2-VASc and HAS-BLED scores, with a similar C-statistic for event prediction. The predictive power of the models with both scores combined, removing overlapping components, was significantly enhanced (p < 0.01) compared to models including either CHA2DS2-VASc or HAS-BLED alone: for mortality, C-statistic: 0.740, compared to 0.707 for CHA2DS2-VASc or 0.646 for HAS-BLED alone. IDI analyses supported the significant improvement for the combined score model compared to separate score models for all outcomes.
Both the CHA2DS2-VASc and the HAS-BLED scores predict mortality similarly in patients with AF, and a combination of their components increases prediction significantly.
Conclusion
The CHA2DS2-VASc score is an essential tool for stroke risk assessment in patients with atrial fibrillation. When used in conjunction with bleeding risk assessment tools like the HAS-BLED score, clinicians can make informed decisions about anticoagulation therapy, balancing the benefits of stroke prevention with the risks of bleeding.
| Feature | CHA2DS2-VASc | HAS-BLED |
|---|---|---|
| Purpose | Assess stroke risk in AF patients | Assess bleeding risk in AF patients |
| Components | CHF, Hypertension, Age, Diabetes, Stroke, Vascular Disease, Sex | Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding, Labile INR, Elderly, Drugs/Alcohol |
| Application | Guide anticoagulation decisions | Inform bleeding risk management |
Popular articles:
tags: #Chad
